For this first human study of luseogliflozin , randomized , single-blind , placebo-controlled , single ascending dose ( 1-25mg ) and multiple ascending dose ( 5 or 10mg/day , 7days ) trials were conducted in healthy male Japanese subjects to investigate safety , pharmacokinetics , and pharmacodynamics .